Amedeo Lonardo

List of Publications by Year in Descending Order

150 papers	9,874 citations	54 h-index	97 g-index
169 ext. papers	12,209 ext. citations	5 avg, IF	6.63 L-index

#	Paper	IF	Citations
150	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*, **2022**, 71, 156-162	19.2	56
149	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome.. *Open Forum Infectious Diseases*, **2022**, 9, ofac003	1	1
148	How Much Vitamin D is Too Much? A Case Report and Review of the Literature. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2021**, 21, 1653-1659	2.2	4
147	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. *Advances in Therapy*, **2021**, 38, 2130-2158	4.1	13
146	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. *Metabolites*, **2021**, 11,	5.6	50
145	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. *Diagnostics*, **2021**, 11,	3.8	22
144	Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 2354-2357	4.5	
143	Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?. *Journal of Clinical Medicine*, **2021**, 10,	5.1	9
142	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. *Journal of Clinical Medicine*, **2020**, 9,	5.1	45
141	Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition. *Diabetes Therapy*, **2020**, 11, 773-777	3.6	1
140	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Annals of Hepatology*, **2020**, 19, 359-366	3.1	33
139	Semi-Quantitative Ultrasonographic Evaluation of NAFLD. *Current Pharmaceutical Design*, **2020**, 26, 3915-3927	3.1	7
138	Perspectives of nonalcoholic fatty liver disease research: a personal point of view **2020**, 1, 85-107		10
137	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. *Metabolism: Clinical and Experimental*, **2020**, 113, 154413	12.7	16
136	Sex and gender: modifiers of health, disease, and medicine. *Lancet, The*, **2020**, 396, 565-582	40	347
135	History of Nonalcoholic Fatty Liver Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	30
134	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. *Advances in Therapy*, **2020**, 37, 1910-1932	4.1	25

133	A critical appraisal of the use of ultrasound in hepatic steatosis. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 667-681	4.2	23
132	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	43
131	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. *Metabolism: Clinical and Experimental*, **2019**, 96, 56-65	12.7	24
130	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. *Hepatology*, **2019**, 70, 1457-1469	11.2	238
129	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. *Atherosclerosis*, **2019**, 284, 66-74	3.1	31
128	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. *Digestive and Liver Disease*, **2019**, 51, 462-470	3.3	26
127	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. *Future Medicinal Chemistry*, **2019**, 11, 2171-2192	4.1	18
126	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. *Acta Diabetologica*, **2019**, 56, 385-396	3.9	42
125	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. *Nature Reviews Endocrinology*, **2018**, 14, 99-114	15.2	170
124	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. *Diseases (Basel, Switzerland)*, **2018**, 6,	4.4	13
123	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Thyroid*, **2018**, 28, 1270-1284	6.2	50
122	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 351-367	4.2	34
121	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. *Journal of Hepatology*, **2018**, 68, 335-352	13.4	298
120	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. *Metabolism: Clinical and Experimental*, **2018**, 79, 64-76	12.7	171
119	Hypothyroidism and nonalcoholic fatty liver disease - a chance association?. *Hormone Molecular Biology and Clinical Investigation*, **2018**, 41,	1.3	8
118	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. *Metabolism: Clinical and Experimental*, **2018**, 87, 1-12	12.7	48
117	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. *Digestive and Liver Disease*, **2017**, 49, 471-483	3.3	179
116	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. *Hepatology*, **2017**, 65, 2122-2123	11.2	2

115	Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. *Aids*, **2017**, 31 Suppl 2, S147-S156	3.5	23
114	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. *Metabolism: Clinical and Experimental*, **2017**, 72, 57-65	12.7	80
113	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. *Advances in Therapy*, **2017**, 34, 1291-1326	4.1	232
112	Nonalcoholic fatty liver disease: Evolving paradigms. *World Journal of Gastroenterology*, **2017**, 23, 6571-6592	5.6	92
111	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. *World Journal of Gastroenterology*, **2017**, 23, 1458-1468	5.6	26
110	Noninvasive diagnosis of nonalcoholic fatty liver disease, is the more expensive the better?. *AME Medical Journal*, **2017**, 2, 171-171	1	1
109	Non-alcoholic fatty liver disease and risk of cardiovascular disease. *Metabolism: Clinical and Experimental*, **2016**, 65, 1136-50	12.7	152
108	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. *Endocrine*, **2016**, 51, 211-21	4	53
107	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. *Digestive Diseases and Sciences*, **2016**, 61, 1246-67	4	75
106	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. *Advances in Therapy*, **2016**, 33, 291-319	4.1	54
105	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. *Medicine (United States)*, **2016**, 95, e2760	1.8	15
104	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. *Digestive and Liver Disease*, **2016**, 48, 333-42	3.3	42
103	Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test. *Indian Journal of Medical Research*, **2016**, 143, 4-7	2.9	3
102	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. *International Journal of Molecular Sciences*, **2016**, 17, 217	6.3	47
101	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *International Journal of Molecular Sciences*, **2016**, 17, 355	6.3	30
100	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World Journal of Gastroenterology*, **2016**, 22, 9674-9693	5.6	69
99	The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. *Hepatology Research*, **2016**, 46, 1074-1087	5.1	82
98	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*, **2016**, 64, 1388-9	11.2	60

97	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *Journal of Gastroenterology and Hepatology (Australia)*, **2016**, 31, 936-44	4	378
96	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. *Journal of Hepatology*, **2016**, 65, 589-600	13.4	640
95	Alcohol and Steatosis: The Japanese Paradox. *EBioMedicine*, **2016**, 8, 23-24	8.8	1
94	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. *Digestive and Liver Disease*, **2016**, 48, 1399-1401	3.3	6
93	Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings. *Journal of Medical Ultrasonics (2001)*, **2015**, 42, 251-5	1.4	5
92	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. *Journal of Clinical Virology*, **2015**, 69, 74-7	14.5	6
91	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. *Digestive and Liver Disease*, **2015**, 47, 997-1006	3.3	279
90	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. *Digestive and Liver Disease*, **2015**, 47, 181-90	3.3	430
89	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 629-50	4.2	57
88	Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. *Liver International*, **2015**, 35, 2340-1	7.9	1
87	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. *Journal of Endocrinological Investigation*, **2015**, 38, 817-25	5.2	52
86	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 603-27	4.2	79
85	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. *Atherosclerosis*, **2014**, 232, 99-109	3.1	97
84	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. *World Journal of Gastroenterology*, **2014**, 20, 1724-45	5.6	160
83	Nonalcoholic fatty liver disease and aging: epidemiology to management. *World Journal of Gastroenterology*, **2014**, 20, 14185-204	5.6	158
82	Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. *World Journal of Gastroenterology*, **2014**, 20, 3410-7	5.6	121
81	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?. *Digestive and Liver Disease* , **2014**, 46, 288-9	3.3	15
80	Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. *World Journal of Gastroenterology*, **2014**, 20, 7089-103	5.6	66

79	Liver and diabetes. A vicious circle. *Hepatology Research*, **2013**, 43, 51-64	5.1	130
78	Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. *Metabolic Syndrome and Related Disorders*, **2013**, 11, 289-95	2.6	21
77	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. *Internal and Emergency Medicine*, **2013**, 8, 297-305	3.7	57
76	From NAFLD in clinical practice to answers from guidelines. *Journal of Hepatology*, **2013**, 59, 859-71	13.4	249
75	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). *Clinics and Research in Hepatology and Gastroenterology*, **2013**, 37, 353-8	2.4	29
74	Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study. *Italian Journal of Medicine*, **2013**, 166-171	0.5	
73	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	80
72	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	70
71	HCV treatment in patients with metabolic syndrome **2013**, 86-97		
70	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-92	3.3	45
69	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. *Hepatology Research*, **2012**, 42, 945	5.1	3
68	Potential for statins in the chemoprevention and management of hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 1654-64	4	50
67	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. *Atherosclerosis*, **2012**, 221, 496-502	3.1	141
66	Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. *Liver International*, **2012**, 32, 1242-52	7.9	124
65	If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?. *Digestive and Liver Disease*, **2012**, 44, 451-2	3.3	11
64	Metabolic alterations and chronic hepatitis C: treatment strategies. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 2215-34	4	55
63	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. *Archives of Medical Research*, **2011**, 42, 337-53	6.6	29
62	Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. *Archives of Medical Research*, **2011**, 42, 690-7	6.6	16

61	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?. *Hepatology*, **2011**, 53, 2142-3; author reply 2143	11.2	7
60	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. *Expert Review of Gastroenterology and Hepatology*, **2011**, 5, 279-89	4.2	48
59	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. *Expert Review of Endocrinology and Metabolism*, **2010**, 5, 403-423	4.1	16
58	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. *Digestive and Liver Disease*, **2010**, 42, 272-82	3.3	159
57	Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2010**, 53, 278; author reply 278-81	3.1	4
56	Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. *Canadian Journal of Gastroenterology & Hepatology*, **2009**, 23, 273-8		24
55	NAFLD and cardiovascular risk: direct evidence for the tale of two ages. *American Journal of Gastroenterology*, **2009**, 104, 1851-2	0.7	8
54	Fatty liver and carotid intimal thickening: a tale of two ages?. *American Journal of Gastroenterology*, **2009**, 104, 1061	0.7	1
53	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. *Internal and Emergency Medicine*, **2009**, 4, 71-3	3.7	8
52	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. *Journal of Gastroenterology and Hepatology (Australia)*, **2009**, 24, 830-40	4	364
51	Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. *Digestive and Liver Disease*, **2009**, 41, 823-8	3.3	61
50	Endocrine and liver interaction: the role of endocrine pathways in NASH. *Nature Reviews Gastroenterology and Hepatology*, **2009**, 6, 236-47	24.2	100
49	Hepatitis C and diabetes: the inevitable coincidence?. *Expert Review of Anti-Infective Therapy*, **2009**, 7, 293-308	5.5	54
48	Article Commentary: Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio. *Clinical Medicine: Endocrinology and Diabetes*, **2009**, 2, CMED.S3518		1
47	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. *Clinical Science*, **2008**, 115, 1-12	6.5	57
46	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. *Hepatology*, **2008**, 47, 361-2	11.2	5
45	Dysmetabolic changes associated with HCV: a distinct syndrome?. *Internal and Emergency Medicine*, **2008**, 3, 99-108	3.7	22
44	Statins in liver disease: a molehill, an iceberg, or neither?. *Hepatology*, **2008**, 48, 662-9	11.2	97

43	The hepatitis C virus-associated dysmetabolic syndrome. *Hepatology*, **2008**, 48, 1018-9; author reply 1019	11.2	11
42	HCV and diabetes. A two-question-based reappraisal. *Digestive and Liver Disease*, **2007**, 39, 753-61	3.3	21
41	Statins and HCV: a complex issue. *Hepatology*, **2007**, 45, 257	11.2	9
40	Is cholangiocarcinoma another complication of insulin resistance: a report of three cases. *Metabolic Syndrome and Related Disorders*, **2007**, 5, 194-202	2.6	10
39	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. *Nutrition, Metabolism and Cardiovascular Diseases*, **2007**, 17, 684-98	4.5	56
38	Gender, fatty liver and GGT. *Hepatology*, **2006**, 44, 278-9	11.2	38
37	Hepatic steatosis and insulin resistance: does etiology make a difference?. *Journal of Hepatology*, **2006**, 44, 190-6	13.4	116
36	Endocrine NAFLD: a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. *Journal of Hepatology*, **2006**, 44, 1196-207	13.4	97
35	Chicken or egg turned into head or belly. *Journal of Hepatology*, **2006**, 45, 454-456	13.4	5
34	17 Beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. *Journal of Gastroenterology and Hepatology (Australia)*, **2006**, 21, 894-901	4	5
33	Hepatitis C and steatosis: a reappraisal. *Journal of Viral Hepatitis*, **2006**, 13, 73-80	3.4	117
32	Fatty liver, carotid disease and gallstones: a study of age-related associations. *World Journal of Gastroenterology*, **2006**, 12, 5826-33	5.6	46
31	Should nonalcoholic fatty liver disease be renamed?. *Digestive Diseases*, **2005**, 23, 72-82	3.2	54
30	Pediatric gallstone disease in familial hypobetalipoproteinemia. *Journal of Hepatology*, **2005**, 43, 188-91	13.4	14
29	Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. *Journal of Gastroenterology and Hepatology (Australia)*, **2005**, 20, 1176-84	4	70
28	Review article: the metabolic syndrome and non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2005**, 22 Suppl 2, 31-6	6.1	44
27	Review article: hepatic steatosis and insulin resistance. *Alimentary Pharmacology and Therapeutics*, **2005**, 22 Suppl 2, 64-70	6.1	58
26	The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. *American Journal of Gastroenterology*, **2005**, 100, 1200-1; author reply 1201-2	0.7	11

25	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. *Hepatology*, **2004**, 39, 1748; author reply 1749	11.2	18
24	Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology*, **2004**, 126, 586-97	13.3	368
23	The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. *European Journal of Gastroenterology and Hepatology*, **2004**, 16, 1043-50	2.2	13
22	Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. *Digestive Diseases and Sciences*, **2003**, 48, 2173-81	4	107
21	Apolipoprotein synthesis in nonalcoholic steatohepatitis. *Hepatology*, **2002**, 36, 514-5; author reply 515	11.2	8
20	Growth hormone plasma levels in nonalcoholic fatty liver disease. *American Journal of Gastroenterology*, **2002**, 97, 1071-2	0.7	33
19	Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?. *European Journal of Gastroenterology and Hepatology*, **2002**, 14, 355-8	2.2	4
18	Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida). *European Journal of Gastroenterology and Hepatology*, **2002**, 14, 1389-92	2.2	5
17	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. *Digestive and Liver Disease*, **2002**, 34, 204-11	3.3	87
16	Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?. *Digestive and Liver Disease*, **2002**, 34, 151	3.3	
15	Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. *Journal of Lipid Research*, **2001**, 42, 1552-1561	6.3	53
14	Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. *Journal of Gastroenterology and Hepatology (Australia)*, **2000**, 15, 775-82	4	42
13	A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). *Journal of Hepatology*, **2000**, 33, 361-70	13.4	51
12	Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?. *Digestive Diseases*, **1999**, 17, 80-9	3.2	59
11	Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. *Digestive Diseases and Sciences*, **1998**, 43, 2489-92	4	27
10	Isolated jejunal Crohn's disease in a young adult presenting as fever of unknown origin. *American Journal of Gastroenterology*, **1998**, 93, 2285-7	0.7	8
9	Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. *Gastroenterology*, **1996**, 111, 1125-33	13.3	82
8	High prevalence of duodenal ulcer in Indochinese immigrants attending an Australian university hospital. *Journal of Gastroenterology and Hepatology (Australia)*, **1994**, 9, 663	4	

7	Portal vein thrombosis (PVT) associated with oral contraceptive steroids (OCS). *Journal of Gastroenterology and Hepatology (Australia)*, **1994**, 9, 314	4	3
6	Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study. *Journal of Clinical Gastroenterology*, **1993**, 17, 101-8	3	40
5	Right colon adenocarcinoma presenting as Bacteroides fragilis liver abscesses. *Journal of Clinical Gastroenterology*, **1992**, 14, 335-8	3	68
4	Solitary Peutz-Jeghers type polyp of the stomach. *Endoscopy*, **1990**, 22, 153	3.4	6
3	Liver cirrhosis as a diabetogenic condition. *Digestive Diseases and Sciences*, **1986**, 31, 111	4	3
2	Familial history in IBD. *Digestive Diseases and Sciences*, **1985**, 30, 410	4	6
1	Lack of correlation between the laboratory findings and a series of steps in the clinical severity of chronic liver disease. *Research in Clinic and Laboratory*, **1984**, 14, 641-8		3